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SUMMARY
Ischemic preconditioning is the phenomenon whereby brief periods of sublethal ischemia protect 
against a subsequent, more prolonged, ischemic insult. In remote ischemic preconditioning 
(RIPC), ischemia to one organ protects others organs at a distance. We created mouse models to 
ask if inhibition of the alpha-ketoglutarate (αKG)-dependent dioxygenase Egln1, which senses 
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oxygen and regulates the HIF transcription factor, could suffice to mediate local and remote 
ischemic preconditioning. Using somatic gene deletion and a pharmacological inhibitor, we found 
that inhibiting Egln1 systemically or in skeletal muscles protects mice against myocardial 
ischemia-reperfusion (I/R) injury. Parabiosis experiments confirmed that RIPC in this latter model 
was mediated by a secreted factor. Egln1 loss causes accumulation of circulating αKG, which 
drives hepatic production and secretion of kynurenic acid (KYNA) that is necessary and sufficient 
to mediate cardiac ischemic protection in this setting.
Graphical Abstract
INTRODUCTION
Brief periods of sublethal ischemia can protect tissues from a subsequent, more severe, 
ischemia-reperfusion (I/R) insult. This phenomenon of ‘ischemic preconditioning’ was first 
observed in experimental models of myocardial infarction (MI) (Murry et al., 1986) and 
later in coronary heart disease patients (Kloner et al., 1995). Patients who have angina 
(ischemic cardiac chest pain) within 48 hours before a MI have better outcomes than patients 
who do not experience preceding angina. Subsequent studies with animals showed that 
ischemia in one coronary artery territory could protect myocardium perfused by another 
coronary artery (Przyklenk et al., 1993), and that coronary effluent from an ischemic heart 
can protect a naive acceptor heart ex vivo (Dickson et al., 1999). Remarkably, ischemia to a 
non-cardiac organ also protects the heart at a distance (Gho et al., 1996). Some, but not all, 
human clinical trials showed that inducing arm ischemia improved outcomes after coronary 
artery interventions associated with iatrogenic cardiac ischemia (Davies et al., 2013) 
(Hausenloy et al., 2015; Meybohm et al., 2015; Thielmann et al., 2013). Many RIPC 
mechanisms have been proposed, including both humoral and neural mechanisms 
(Przyklenk, 2013).
The HIF transcription factor, which consists of a labile α subunit and a stable β subunit, 
accumulates during hypoxia and activates genes whose products promote cellular survival 
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under ischemic conditions. The HIFα subunit is regulated through prolyl hydroxylation by 
α-ketoglutarate (αKG) dependent-dioxygenases known as EGLNs (also called PHDs). Of 
the 3 EGLN paralogs, EGLN1 is the primary regulator of HIFα (Kaelin and Ratcliffe, 2008). 
Hydroxylated HIFα is bound by the von Hippel Lindau (VHL) tumor suppressor protein, 
which marks HIFα for degradation. EGLNs require O2, and HIFα hydroxylation is thus 
impaired when O2 is limited, allowing HIFα accumulation. In sum, EGLNs act as ‘O2 
sensors’ in metazoans and coordinate cellular responses that promote adaptation to hypoxia 
and ischemia (Kaelin and Ratcliffe, 2008).
Cardiac-specific Egln1 inactivation during late embryogenesis protects adult mice from MI 
after permanent coronary artery occlusion (Hölscher et al., 2011). Similarly, mice 
homozygous for a hypomorphic Egln1 allele have less myocardial damage after I/R than 
Egln1 +/+ mice (Hyvärinen et al., 2010). Conversely, both local and remote preconditioning 
are attenuated in Hif1α +/− mice (Cai et al., 2007; 2013). Collectively, these results support 
that HIF protects the heart during acute MI. However, chronic manipulation of HIF causes 
adaptations, such as increased angiogenesis and decreased mitochondria, that might be 
irrelevant to therapies aimed at acutely modulating the HIF response in patients with acute 
myocardial ischemia and impending MI (Huang et al., 2008). Moreover, a recent report 
challenged the conclusion that HIF1α is required for RIPC (Kalakech et al., 2013).
Others have acutely inactivated Egln at the time of experimental MI. The pharmacological 
prolyl hydroxylase inhibitors, FG0041, GSK360, and 2-(1-chloro-4-hydroxyisoquinoline-3-
carboxamido) acetate (ICA) have been shown to be cardioprotective in rodents (Bao et al., 
2010; Nwogu et al., 2001; Vogler et al., 2015). However, these drugs might inhibit other α-
ketoglutarate (αKG)-dependent dioxygenases in addition to the Eglns. Indeed FG0041 was 
initially tested in this setting because it inhibits the collagen prolyl hydroxylases and only 
later shown to inhibit the Eglns (Nwogu et al., 2001). Several groups reported ischemic 
cardioprotection in mice after intraperitoneal (i.p.) (Natarajan et al., 2006) or intraventricular 
(Eckle et al., 2008) injection of naked Egln1 siRNAs or intramyocardial injection of a 
plasmid encoding an Egln1 shRNA (Huang et al., 2008). Although these interventions 
reportedly induced HIF, the bioavailability of siRNAs and plasmids delivered in this way is 
suspect. Moreover, it was later revealed that the Egln1 siRNA used in one of these studies 
targeted a collagen prolyl hydroxylase rather than Egln1, raising questions about specificity 
(Natarajan et al., 2006). Finally, a recent study reported that intramuscular injection of an 
adenovirus encoding HIF1α acutely protected the heart at a distance (Cai et al., 2013).
RESULTS
Chronic Egln1 Inactivation in Cardiomyocytes Protects Against I/R Injury
We used genetic and pharmacological tools to probe the role of Egln1 and HIF in local and 
remote ischemic preconditioning. Adult mice in which Egln1 has been deleted in the heart at 
~E12.5 experience less myocardial damage after permanent occlusion of the left anterior 
descending (LAD) coronary artery than do control mice, implying that Egln1 plays a 
cardiac-intrinsic role in cardioprotection (Hölscher et al., 2011). To ask whether this is also 
true in an ischemia-reperfusion (I/R) model, which more closely mimics myocardial injury 
during clinical MI, we crossed mice with a conditional (floxed or “F”) Egln1 allele with a 
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mouse strain expressing Cre recombinase under the control of the cardiac-specific alpha 
myosin heavy chain (MHC) promoter (Agah et al., 1997). We confirmed inactivation of 
Egln1 in the heart, but not skeletal muscle, liver and kidney, in Egln1F/F;MHC-Cre mice 
(Figure S1A). As expected, heart-specific Egln1 inactivation induced HIF target genes 
(Figure S1B). Moreover, cardiac-specific Egln1 inactivation was cardioprotective in mice 
subjected to cardiac I/R injury (Figure S1C) and in isolated hearts in a Langendorff model of 
global myocardial ischemia, as reflected by a faster recovery (lowering) of end-diastolic 
pressures compared to control mice (Figure S1D). Therefore chronic Egln1 inactivation 
confers cardiac-intrinsic protection against both permanent and transient cardiac ischemia.
Acute Systemic Egln1 Inactivation Protects the Heart Against I/R Injury
We next tested an Egln inhibitor, FG-4497 (Fibrogen; (Laitala et al., 2012; Robinson et al., 
2008)), in the same cardiac I/R injury models. We first confirmed that FG-4497 induced 
HIF1α in HL-1 cardiomyocytes (Figure 1A) and inhibited Egln in vivo as determined by 
imaging mice that ubiquitously express a HIF1α-luciferase fusion reporter (Safran et al., 
2006). (Figure 1B). Notably, FG-4497 stabilized HIF1α and induced HIF target genes in the 
heart (Figure 1C and 1D). Pretreatment with FG-4497 decreased cardiac injury after I/R in 
the Langendorff model (Figure 1E) and decreased MI size in mice subjected to LAD 
occlusion/release in vivo by ~30% (Figure 1F). Importantly from a clinical perspective, 
FG-4497 treatment at the time of reperfusion also substantially reduced infarct sizes (Figure 
1G).
Next we used Egln1F/F;CreER mice that ubiquituously express a tamoxifen (TAM)-
activatable CreER fusion protein (Minamishima et al., 2008). Giving such mice TAM for 
three days significantly decreased Egln1 mRNA levels in the heart, kidney and skeletal 
muscle compared to TAM-treated Egln1+/+;CreER mice (Figure 2A), and induced HIF1α 
protein (Figure 1C) and HIF-responsive mRNAs in the heart (Figure 2B). Acute, systemic, 
inactivation of Egln1 decreased myocardial injury in the Langendorff I/R model (Figure 2C) 
and decreased MI size in mice subjected to cardiac I/R in vivo compared to TAM-treated 
Egln1+/+;CreER control mice (Figure 2D). Consistent with Egln1 being the relevant target of 
FG-4497, the effects of the combined Egln1 gene deletion and pharmacologic Egln 
inhibition were subadditive (Figure 2E). Therefore acute systemic Egln1 inactivation 
protects against cardiac I/R injury.
Skeletal Muscle Egln1 Deletion Confers Remote Cardiac Ischemic Protection
Protection against cardiac I/R injury after systemic Egln1 loss could reflect a cell-
autonomous effect in cardiomyocytes, a non-cell autonomous “remote” effect on the heart, 
or both. To explore non-cell autonomous effects, we made mice in which Egln1 could be 
conditionally inactivated specifically in skeletal muscle. Egln1F/F and Egln1+/+ mice were 
crossed with mice expressing a TAM-dependent CreER transgene driven by a skeletal 
muscle-specific promoter (human alpha actin; HSA-Cre-ERT2) (Schuler et al., 2005). 
Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 mice were given TAM or vehicle for 
five days and sacrificed 5 days later. Egln1 was recombined in multiple skeletal muscle 
groups of TAM-treated Egln1F/F;HSA-Cre-ERT2 mice, but not in other tissues tested, such 
as the heart and liver (Figure S2A). Egln1 deletion decreased skeletal muscle Egln1 mRNA 
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and protein levels (Figure 3A and 3B). Importantly, hearts from TAM-treated 
Egln1F/F;HSA-Cre-ERT2 mice did not exhibit decreased Egln1 mRNA (Figure 3A), 
decreased Egln1 protein (Figure S2B), increased HIF1α protein (Figure S2C), or increased 
HIF-responsive mRNAs (Figure S2D and S2E).
We next asked whether Egln1 deletion in the skeletal muscle can protect the heart at a 
distance. TAM-treated Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 mice were 
subjected to in vivo cardiac I/R injury. Deletion of Egln1 in the skeletal muscle reduced MI 
size after cardiac I/R injury by ~40% (Figure 3C). HIF induces nitric oxide synthase in 
certain cell types (Coulet et al., 2003), which might protect the heart by increasing nitric 
oxide production and decreasing afterload. We did not, however, detect differences in blood 
pressures between TAM-treated Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 
mice (Figure S2F), nor alterations of blood nitrite levels (Figure S2G) (Coulet et al., 2003). 
These data show that Egln1 inactivation in skeletal muscles confers remote ischemic 
cardioprotection.
Remote Ischemic Protection by Skeletal Muscle Egln1 Gene Deletion is Mediated by a 
Humoral Factor
It is debated whether an intact peripheral nervous system, a soluble humoral factor, or both 
are required for RIPC (Przyklenk, 2013). To ask whether a humoral factor mediates RIPC in 
mice with skeletal muscle-specific Egln1 deletion, we performed a parabiosis experiment. 
Parabiosis pairings were made between wild-type (WT) mice (“recipient” partner) and either 
Egln1F/F;HSA-Cre-ERT2 or Egln1+/+;HSA-Cre-ERT2 mice (“donor” partner). The donor 
mice were given TAM for 5 days, and 5 days later the recipient mice were subjected to 
cardiac I/R injury. Evan’s blue dye injected 2 days later confirmed shared circulation in both 
types of pairings (Figure 3E). Genotyping confirmed Egln1 deletion specifically in the 
skeletal muscle of TAM-treated Egln1F/F;HSA-Cre-ERT2 donor mice (Figure 3D). Recipient 
parabiosis partners of Egln1F/F;HSA-Cre-ERT2 mice had ~30% smaller MIs than did 
recipient partners of Egln1+/+;HSA-Cre-ERT2 mice (Figure 3F). These data argue that a 
humoral factor mediates RIPC after Egln1 deletion in skeletal muscle.
Egln1 Inactivation Alters Circulating Tryptophan Metabolites
To look for circulating cardioprotective factors that were upregulated after skeletal muscle 
deletion of Egln1, we profiled serum cytokines in TAM-treated Egln1F/F;HSA-Cre-ERT2 
and Egln1+/+;HSA-Cre-ERT2 mice. None of the 144 cytokines profiled were upregulated 
>10% after Egln1 loss in skeletal muscle (Figure S3A). In particular, we did not detect 
changes in the levels of IL-10 and EPO, which have previously been implicated in RIPC 
(Cai et al., 2013; 2003) (Figure S3B). In addition, pretreatment with a JAK1/2 inhibitor 
(Ruxolitinib), which blocks signaling by many cytokine receptors, did not abrogate RIPC in 
our model (Figure S3C). We concluded that the humoral mediator of RIPC in our model was 
not one of the cytokines examined or a cytokine that signals through JAK1/2.
Next, we analyzed gene expression profiles in skeletal muscles from TAM-treated 
Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 mice, and compared differentially 
regulated genes to a published list of genes predicted to encode secreted proteins (Wu et al., 
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2010). 41 genes were differentially expressed in the skeletal muscles from TAM-treated 
Egln1F/F;HSA-Cre-ERT2 (q<0.1), 7 of which encode proteins predicted to be secreted 
(Natarajan et al., 2006; Wu et al., 2010). Real-time PCR confirmed up-regulation of 2 of 
these 7 mRNAs, PLAC9 and LYPD1 (Figure S3D). Relatively little is known of the biologic 
function of PLAC9 and neither gene, to our knowledge, is known to encode circulating 
polypeptides.
We next looked for a potential small molecule mediator(s) of cardioprotection. Blood was 
collected from TAM-treated Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 mice, 
and serum and plasma metabolites were profiled by LC-MS. Among the metabolites with 
statistically significant differences were various tryptophan (TRP)-related metabolites 
(Figure 4A). To narrow the list of possible mediators of remote cardiac I/R protection, we 
did an orthogonal experiment by profiling selected serum metabolites in WT mice given 
FG-4497 or vehicle (Figure 4B). We hypothesized that the cardioprotective mediator(s) 
would be induced by both genetic and pharmacological Egln1 inhibition, that systemic 
Egln1 inhibition might alter levels of the metabolite(s) of interest to an even greater extent 
than skeletal muscle deletion of Egln1, and that the cardioprotective metabolite(s) would be 
induced rapidly by FG-4497 since FG-4497 protected hearts even when administered after 
ischemic injury (Figure 1G). Strikingly, we observed significant changes in circulating TRP 
metabolites 10 minutes after FG-4497 treatment (Figure 4B).
The Tryptophan Metabolite Kynurenic Acid Mediates Remote Ischemic Protection after 
Egln1 Inactivation
We focused on the TRP metabolite kynurenic acid (KYNA) as a possible cardioprotective 
agent because KYNA is tissue protective in models of cerebral and renal injury (Germano et 
al., 1987; Pundir et al., 2013; Zwilling et al., 2011). KYNA production from TRP is 
regulated by a rate-limiting pyrolase TRP dioxygenase (TDO) in the liver or indoleamine 2,3 
dioxygenase (IDO) in peripheral tissues, as well as by αKG-dependent transamination 
performed by kynurenine transaminases (KAT; Figure 4C) (Agudelo et al., 2014). We 
confirmed that the mass spectrometry ion counts we obtained for serum KYNA and αKG in 
mice were in the linear ranges for their respective assays and consistent with serum 
concentrations of ~5 μM and ~50 μM, respectively in untreated WT mice (Figure S3E–F).
To ask whether KYNA was needed for cardiac I/R protection after skeletal muscle Egln1 
deletion, TAM-treated Egln1F/F;HSA-Cre-ERT2 and Egln1+/+;HSA-Cre-ERT2 controls were 
given 1-methyl tryptophan (1MT), a reversible inhibitor of both TDO and IDO, before 
cardiac I/R injury. 1-MT partially abrogated the protection caused by skeletal muscle 
deletion of Egln1, but did not affect MI sizes in control animals (Figure 4D). Conversely, 
pretreatment of WT mice with KYNA (Andiné et al., 1988) or the KYNA mimetic L689,560 
decreased MI size compared to vehicle-treated mice (Figure 4E and 4F). Cardioprotection 
by KYNA appeared to be heart-autonomous, as addition of KYNA to the perfusate of 
isolated hearts improved ischemia tolerance in Langendorff assays (Figure 4G). These data 
argue that KYNA is necessary and sufficient for remote cardiac ischemic protection 
following Egln1 inhibition.
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Egln1 Inhibition Generates KYNA via Altered Systemic αKG Metabolism
KYNA was not induced by inactivating Egln1 in various cell culture models (Figure S4A) 
and mRNAs linked to TRP metabolism were not induced in skeletal muscle after 
inactivating Egln1 (Figure S4B), suggesting that the increased KYNA observed after Egln1 
inactivation in skeletal muscle in vivo was indirect and non-cell autonomous. In order to 
determine the organ(s) producing KYNA in our model, mice were infused with U-13C-TRP 
and then given FG-4497 (Figure S4C). Newly formed U-13C-KYNA was detected in the 
serum, liver, kidneys, and lung, but not in skeletal muscle (Figure 5A). We concluded that 
KYNA is made by a tissue other than muscle after Egln1 inactivation in skeletal muscle.
Hepatic KYNA production was intriguing because the TRP metabolites n-
methylnicotinamide (NMN) and niacinamide (NAM), which can be made only by the liver 
and the kidney, were among the serum metabolites downregulated by skeletal muscle Egln1 
loss (Figure 4A). Moreover, our U-13C-TRP studies confirmed conversion of TRP to NMN 
and NAM in the liver and not the kidney (data not shown). Up-regulation of circulating 
KYNA combined with down-regulation of NMN and NAM suggested altered hepatic TRP 
metabolism after Egln inhibition (Figure 4C).
How might targeting Egln—via systemic FG-4497 administration or skeletal muscle 
deletion of Egln1—regulate hepatic TRP metabolism? We found no differences in mRNA 
levels for KYNA pathway enzymes in the liver (Figure S4D) of TAM-treated Egln1F/F;HSA-
Cre-ERT2 mice compared to control mice. Moreover, serum KYNA was increased 10 
minutes after systemic FG-4497 administration (Figure 4B). These two observations 
suggested that control of KYNA by Egln1 in this model did not involve transcriptional 
changes in the liver.
KYNA production is regulated by KATs (Agudelo et al., 2014) which, like Egln1, require 
αKG as a co-substrate. αKG accumulates under hypoxic conditions and after pVHL loss 
(with consequent HIF stabilization) (Metallo et al., 2012; Wise et al., 2011), suggesting that 
αKG might link Egln1 inactivation to KYNA production. Indeed, αKG levels were elevated 
in the serum (Figure 4A), skeletal muscle, and liver in TAM-treated Egln1F/F;HSA-Cre-
ERT2 mice compared to control mice (Figure 5B) and in the livers of mice given FG-4497 
compared to vehicle (Figure 5C). Systemic administration of αKG, like FG-4497, rapidly 
(10 minutes) increased circulating and hepatic KYNA levels (Figure 5D). Importantly, 
systemic αKG administration also protected hearts subjected to I/R injury in vivo (Figure 
5E) and ex vivo in the Langendorff model (Figure 5F). In notable contrast to KYNA, 
however, αKG did not provide I/R protection when added directly to the perfusate in the 
Langendorff model (Figure 5F), consistent with the idea that αKG protects in vivo by 
increasing hepatic KYNA production.
HIF-independent Regulation of αKG Metabolism by Egln1
In cell culture models, hypoxia and FG-4497 both increased αKG levels (Figure 6A–B). 
This was true whether αKG levels were normalized to cell number, or to the dioxygenase 
product succinate (αKG/Suc ratio) or to the transamination partner glutamate (αKG/Glu 
ratio). FG-4497 had minimal effect on αKG in cells Egln1−/− cells, supporting an on-target 
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drug effect (Figure S5A). The rapid induction of αKG (Figure 5C) and KYNA (Figure 4B) 
after Egln1 inactivation in vivo suggested that the accumulation of αKG in this setting does 
not require the canonical Egln1 target HIFα and transcriptional induction of HIF target 
genes. Consistent with this view, FG-4497 and hypoxia increased the αKG/Glu ratio in 
Hepa-1c1c7 cells that lack the requisite HIFα transcriptional partner ARNT (Figure 6C) and, 
accordingly, cannot activate a HIF-responsive luciferase reporter after Egln inhibition 
(Figure 6D) despite HIF1α stabilization (Figure 6E). Taken together, our data suggest that 
Egln inhibition in skeletal muscle—in a manner independent of HIF transcriptional activity
—increases circulating and hepatic αKG, which drives the production of the 
cardioprotective metabolite KYNA.
We hypothesized that Egln1 inhibition increases αKG levels as a direct or indirect 
consequence of altered decarboxylation of its co-substrate, αKG. Egln1 is highly active, 
with a maximum rate of αKG decarboxylation of 45 mol/mol Egln1/min (Hirsilä et al., 
2005). We estimate that 1 gram of skeletal muscle protein contains approximately 6.11 
picomoles of Egln1, which based on the above rate, could decarboxylate 275 picomoles 
αKG /minute (Figure S5B–F). As a point of reference, this flux is ~0.5% of the skeletal 
muscle glycolytic rate (Kummitha et al., 2014).
To assess this predicted high rate of flux further, we traced the conversion of esterified, 13C-
αKG to succinate over time in cells. 13C-αKG was rapidly converted to 13C-succinate in 
both WT (Figure 6F) and Cytochrome B mutant 143B cybrid cells (Figure S5G–H). This 
conversion was enhanced by ectopic expression of WT, but not catalytically-defective, 
EGLN1 (Ladroue et al., 2008), and was decreased by 10-minute pretreatment with FG-4497. 
These effects of manipulating EGLN1 were not due to indirect changes in O2 consumption 
because Cytochrome B mutant cells lack an intact electron chain and are respiration 
defective (Sullivan et al., 2015). These experiments yielded an estimated rate of αKG 
decarboxylation by EGLN1 of ~200 picomoles/min/g of tissue (Figure S5I). The actual rate 
might be higher in tissues with high metabolic rates such as the heart, muscle and liver. 
Collectively, these findings support a high rate of EGLN1-dependent conversion of αKG to 
succinate and implicate EGLN1 in the direct control of central carbon metabolism.
DISCUSSION
Cardiovascular diseases such as MI and stroke are the leading cause of death worldwide. 
Our findings confirm and extend earlier claims that chronic Egln1 inactivation, as well as 
chronic HIF stabilization, protects the heart against I/R injury (Cai et al., 2007; Hyvärinen et 
al., 2010) and permanent ligation injury (Bao et al., 2010; Nwogu et al., 2001). However, 
prolonged HIF activation can ultimately cause deleterious cardiac effects, culminating in 
dilated cardiomyopathy (Bekeredjian et al., 2010; Huang et al., 2004; Moslehi et al., 2010). 
Moreover, these preclinical models of chronic HIF activation do not necessarily address the 
utility of acutely inactivating Egln1 in the pre or peri-infarct setting. Using both a 
conditional Egln1 allele and a small molecule Egln1 inhibitor we found that acute Egln 
inactivation protects the heart against I/R injury. Importantly, the use of a pharmacological 
inhibitor, in contrast to the genetic model, allowed us to model drug treatment at the time of 
injury, where we again observed significant protection. Nonetheless, EglN1 inhibition might 
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ultimately be most effective when used prophylactically, such as in the setting of unstable 
angina or elective cardiac surgery, which are associated with a high risk of an ischemic 
insult.
The cardioprotective effects observed after acute, systemic, Egln1 inactivation are likely to 
involve both cardiomyocyte-intrinsic HIF-dependent effects as well as remote effects. Since 
Egln1 is ubiquitously expressed and would predictably be inhibited by tissue ischemia, such 
remote effects could potentially underlie RIPC. Indeed, we found that acute, genetic ablation 
of Egln1 in skeletal muscles protects the heart at a distance.
We discovered that acute Egln1 inhibition leads to rapid, HIF-independent, systemic 
induction of αKG, which drives hepatic transamination of the TRP metabolite kynurenine 
(KYN) to produce KYNA, presumably by stimulating one of several known αKG-dependent 
KATs. Notably, perivenous hepatocytes are able to utilize circulating αKG to support 
transamination reactions (Stoll and Hüssinger, 1989). KYNA was previously shown to be 
tissue protective in models of cerebral and renal ischemia (Andiné et al., 1988; Germano et 
al., 1987; Pundir et al., 2013). We observed that KYNA is cardioprotective both in vivo and 
ex vivo, and is both necessary and sufficient for remote cardiac protection after skeletal 
muscle inactivation of Egln1. Although KYNA is critical in our model, additional humoral 
and neural factors might also contribute to RIPC.
Notably, KYNA is elevated in survivors of cardiac arrest—a condition of systemic ischemia
—in both animal models and in humans (Ristagno et al., 2013). Also, the KYNA precursor, 
KYN, is induced in hypoxic cells as part of a ‘catabolic signature’ of hypoxia (Frezza et al., 
2011). Additionally the downstream kynurenine pathway metabolite anthranilate is one of 
the few metabolites elevated for sustained periods after MI, suggesting changes in TRP 
metabolism during cardiac ischemia (Lewis et al., 2008). These observations underscore a 
potential role of TRP metabolism in the response to ischemia.
Our data suggest that acute inactivation of Egln1, which utilizes αKG as a co-substrate, 
causes the rapid accumulation of αKG. The rate of αKG decarboxylation by Egln1 is 
predicted to be high because of the rapid turnover of its hydroxylation targets, the HIFα 
proteins. Biochemical experiments also suggest that the EglNs decarboxylate αKG in an 
uncoupled reaction in the absence of a polypeptide substrate so long as adequate reducing 
equivalents are available (Hirsilä et al., 2005), although the relative importance of coupled 
and uncoupled αKG decarboxylation by the Eglns in vivo is unknown. Nonetheless, our 
experiments with 13C-αKG are consistent with a very high rate of αKG metabolism by 
Egln1. Although it is difficult to predict changes in metabolite pool sizes from changes in 
flux rates, the rapid induction of αKG after Egln1 inhibition is likely due, at least in part, to 
the abrupt decrease in αKG utilization by Egln1. Notably, acutely inhibiting an αKG flux of 
nanomoles per minute on a whole mouse basis could theoretically alter serum αKG 
concentrations in the physiological (μM) range. It is also possible that Egln1 has a non-
canonical substrate that acutely influences αKG pool sizes, or that changes in Egln1 
metabolic flux indirectly alter other processes that ultimately impact αKG pool sizes. 
Finally, decreased αKG uptake by tissues after Egln1 loss might contribute to redistribution 
of αKG in vivo.
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KYNA is an agonist for the aryl hydrocarbon receptor, where it can affect transcription, and 
a ligand for various receptors including NMDA receptors, neuronal cholinergic α7 nicotine 
receptors, and the orphan G-coupled receptor GPR35. Interestingly, GPR35 is a HIF target 
that is induced during cardiac remodeling (Ronkainen et al., 2014). Clearly additional 
studies are required to determine how KYNA protects the heart.
The mediator(s) of RIPC have been sought for more than 20 years, in hopes they could be 
used to treat cardiovascular diseases. Two recent large, randomized, studies, however, did 
not find a benefit of RIPC in patients undergoing cardiac surgery (Hausenloy et al., 2015; 
Meybohm et al., 2015). Our findings suggest that the efficacy of RIPC could be influenced 
by many variables including duration and magnitude of ischemia, skeletal muscle mass, 
hepatic function, and concurrent medications, including drugs metabolized in the liver, such 
as anesthetics. With respect to the latter, these two studies required and allowed, 
respectively, the use of propofol, which has been suggested to block RIPC (Kottenberg et al., 
2012; 2014). Direct administration of KYNA might be a more robust way to protect tissues 
such as the heart than past attempts to induce RIPC with controlled regional ischemia.
EXPERIMENTAL PROCEDURES
Materials
FG-4497 was obtained from FibroGen, Inc. (San Francisco, CA, USA), and dosed at 50 
mg/kg for mouse studies and 30 μM concentration for in vitro studies. 5 mg/ml 1-methyl-
DL-tryptophan (1-MT; Sigma-Aldrich, St. Louis, MO, USA) was added to the drinking 
water of mice.
Cell Culture
Immortalized mouse embryonic fibroblasts (MEFs) were made from Egln1+/+ and Egln1−/− 
littermates and maintained in pyruvate-free DMEM containing 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin (P/S). Hepa-1c1c7 mouse hepatoma cells (ATCC, 
Manassas, VA, USA) were grown in MEM (Corning Mediatech, Manassas, VA, USA) 
supplemented with 10% FBS and 1% P/S. 143B cybrid cells (Sullivan et al., 2015) were 
grown in DMEM supplemented with 10% FBS, 1% P/S, 1 mM sodium pyruvate, and 0.1 
mg/ml uridine.
Retroviruses
A Flag-tagged WT human EGLN1 cDNA (Lorenzo et al., 2014) was subcloned into a pLenti 
vector with a CMV promoter. The H374R mutation (c.1121A→G) was made by site-
directed mutagenesis. The 3XHRE luciferase reporter (Yan et al., 2007) was shuttled into a 
promoterless lentivirus. Lentiviruses were made by co-transfection (TransIT, Mirus Bio 
LLC, Madison, WI, USA) of 293TL cells with expression vectors along with the packaging 
constructs. Cells were infected by centrifugation in the presence of viral supernatants and 
polybrene.
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Mice
The Egln1F/F, αMHC-Cre, CreER, HSA-Cre-ERT2 and ODD-Luc mice were previously 
described (Minamishima et al., 2008; Moslehi et al., 2010; Safran et al., 2006; Schuler et al., 
2005). Egln1 was deleted by treating age- and sex-matched Egln1F/F mice harboring a TAM-
regulated Cre with TAM 1 mg/dose i.p.. For studies in HSA-Cre-ERT2 mice, TAM was 
given daily for 5 days and mice were studied 5 days later. For studies in CreER mice, three 
days of TAM were given and mice were analyzed on day 4 (Minamishima et al., 2008).
In Vivo Bioluminescence Imaging
In vivo bioluminescence imaging was done as previously described (Safran et al., 2006). 
Mice were given FG-4497 (i.p.) at the stated doses 2 hours before D-luciferin (150 mg/kg, 
i.p.).
Ischemia-Reperfusion Injury
8–12 week old mice were anesthetized, intubated and ventilated. Left thoractotomy was 
performed, and the left anterior descending (LAD) artery was ligated with a 6.0 silk suture. 
Ischemia was confirmed by myocardial blanching and electrocardiographic (ECG) evidence 
of injury. Five minutes into ischemia, 50 μL of fluorescent microspheres (10 μM 
FluoSpheres, Molecular Probes, Eugene, OR, USA) was injected into the left ventricular 
cavity. The LAD ligature was released 30 minutes later and reperfusion confirmed visually 
by ECG. Overall survival was 70–80% at 24 hours. Mice were terminally anesthetized 24 
hours after ischemia with ketamine/xylazine followed by cervical dislocation, hearts were 
harvested, and the ventricles were sectioned from apex to base in 2 mm sections. Sections 
were incubated in 2% (wt/vol) triphenyltetrazolium (TTC, Sigma) in phosphate-buffered 
saline at 25°C for 30 minutes. Infarct size and area at risk (AAR) was quantified from light 
and fluorescent micrographs of myocardial sections using Adobe Photoshop. Percent MI 
was calculated as the infarcted area divided by the AAR. Assessment of I/R injury in the 
Langendorff Model was as described (Liao et al., 2012).
Parabiosis surgeries were done as per published protocols (Wright et al., 2001). Ten days 
after the parabiosis operation, a subset (n=2) of parabiosed mice were used to confirm the 
presence of cross-circulation of blood by Evan’s Blue dye injection. One mouse in each 
joined pair was injected with 100 μl of Evan’s Blue into the retro-orbital venous plexus. 
Peripheral blood was collected before and 2 hours after injection. Cardiac I/R injury was 
performed as described above. The “recipient” partner (mouse undergoing I/R) was 
anesthetized and intubated per protocol while “donor” partners was anesthetized using 
ketamine at 80 mg/kg IP for the duration of the surgery.
In Vivo Delivery of Stable Isotope Tracers
Conscious, unrestrained mice were infused with 0.19 mg/kg/minute U-13C-TRP (Cambridge 
Isotopes Laboratories, Inc., Tewksbury, MA, USA) in normal saline via a central venous 
catheter. At 30-minute intervals, 20 μl of blood was sampled from an arterial catheter and 10 
μl aliquot of plasma was snap-frozen in liquid N2. After 90 min, a 50 mg/kg bolus of 
FG-4497 was dosed over 4 minutes. Mice were sacrificed by sodium pentobarbital (120 mg/
kg), and tissues collected.
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Metabolite Extraction and Mass Spectrometry
For metabolic analyses organs were quickly dissected from euthanized mice. ~50 mg tissue 
sections were clamped between liquid nitrogen-cooled flat forceps, weighed, and ground. 
Metabolites were extracted in methanol:water:chloroform (6:3:4) by vortexing for 10 
minutes at 4°C followed by centrifugation at 10,000 x g for 10 minutes at 4°C. Aliquots of 
aqueous fractions, in proportion to tissue exact mass, were dried in a refrigerated centrivap. 
For cell culture experiments, sample extraction were done as described (Fendt et al., 2013).
For gas chromatography mass spectrometry (GCMS) analyses, dried metabolites were 
derivatized and analyzed as described (Fendt et al., 2013). Reported are the dominant ions 
for derivatives of alpha-ketoglutarate (αKG, m/z 346), Succinate (Suc, m/z 289), and 
Glutamate (Glu, m/z 432). 13C mass isotopes were quantified and corrected for natural mass 
isotope abundances. For liquid chromatography mass spectrometry (LC-MS) analysis of 
tissue metabolites, dried metabolites were resuspended in acetonitrile:methanol:formic acid 
(75:25:0.5 v:v:v) and samples were analyzed in positive and negative ion mode using via 
hydrophilic interaction liquid chromatography (HILIC) MS analyses (Avanesov et al., 2014; 
Townsend et al., 2013; Wang et al., 2011).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Inhibition of EglN1 locally or at a distance protects the heart against I/R injury
• Remote ischemic protection after EglN1 loss is mediated by a humoral factor
• Diversion of the EglN co-substrate αKG stimulates hepatic kynurenic acid 
production
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Figure 1. Acute Systemic Inhibition of Egln Protects Against Cardiac I/R Injury
(A) Representative immunoblots of HL-1 cardiomyocytes treated with FG-4497 for 6 hours.
(B) Bioluminescent images of representative mice expressing a HIF-luciferase fusion protein 
3 hours after being given intravenous (i.v.) FG-4497.
(C) HIF1α protein levels in the hearts of mice given 50 or 100 mg/kg FG-4497 i.v., as 
indicated by the triangle, or after systemic Egln1 genetic deletion. Egln1F/F; Cre-ER and 
Egln1+/+; Cre-ER mice were given TAM for 5 days before sacrifice.
(D) Real-time PCR assays of mRNAs in the heart 3 hours after i.p. administration of 50 
mg/kg FG-4497 (n=5) or vehicle (n=4). Data shown are mean fold changes ± SEM. 
*p<0.05, **p<0.01, Student’s t-test, FG-4497 versus vehicle (Veh.).
(E) LVEDP in Langendorff assays of global I/R injury. Mice were given 50 mg/kg FG-4497 
i.v. or Veh. 2 hours before cardiectomy. Data shown are mean pressures ± SEM, n = 8 in 
each group. *p<0.05, **p<0.01, Student’s t-test.
(F) MI size after cardiac I/R injury in mice given 50 mg/kg FG-4497 i.p. or Veh. two hours 
before in vivo cardiac I/R injury. Data are normalized to the Area-at-Risk (AAR). Data 
shown are means ± SEM, n = 8 FG-4497 and n = 7 vehicle. *p<0.05, Student’s t-test. 
Representative photographs of TTC-stained hearts are shown.
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(G) MI size relative to AAR in mice given 50 mg/kg FG-4497 i.p. or Veh. at the time of 
LAD reperfusion. Data shown are means ± SEM, n = 6 FG-4497 and n = 5 vehicle. *p<0.05, 
Student’s t-test. Representative photographs of TTC-stained hearts are shown.
Olenchock et al. Page 19
Cell. Author manuscript; available in PMC 2017 February 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Acute Systemic Deletion of Egln1 Protects Against Cardiac I/R Injury
(A) Real-time PCR assays of Egln1 mRNA in tissues from Egln1F/F; CreER and Egln1+/+; 
CreER mice. Mice were given TAM for 3 days and sacrificed 3 days later. Data shown are 
mean fold changes ± SEM, n = 4 in each group. *p<0.05, **p<0.01, ***p<0.01, Student’s t-
test, difference in mRNA levels between Egln1F/F; CreER and Egln1+/+; CreER mice.
(B) Real-time PCR assays of select HIF-responsive mRNAs in the hearts from TAM-treated 
Egln1F/F; CreER and Egln1+/+; CreER mice. Data shown are mean fold changes ± SEM, n = 
4 in each group. *p<0.05, **p<0.01, ***p<0.01, Student’s t-test, difference in mRNA levels 
between Egln1F/F; CreER and Egln1+/+; CreER mice.
(C) LVEDP in Langendorff assays of global I/R injury. Mice were given TAM as in (A) 
before cardiectomy. Data shown are mean pressures ± SEM, n = 6 in each group. **p<0.01, 
***p<0.01, Student’s t-test.
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(D) MI size relative to AAR after in vivo cardiac I/R injury in TAM-treated Egln1F/F; CreER 
and Egln1+/+; CreER mice. Data shown are means ± SEM, n = 10 mice per group. **p<0.01, 
Student’s t-test.
(E) MI size after cardiac I/R injury in TAM-treated Egln1F/F; CreER and Egln1+/+; CreER 
mice, pre-treated with 50 mg/kg FG-4497 i.v. or Veh. two hours before cardiac I/R injury. 
Data shown are means ± SEM, n = 8 FG-4497 and n = 7 vehicle groups. ***p<0.001, 
Student’s t-test, differences MI sizes compared to Veh.-treated Egln1+/+; CreER mice.
See Figure S1.
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Figure 3. Skeletal Muscle Egln1 Deletion Confers Remote Cardioprotection via a Circulating 
Factor
(A) Real-time PCR assays of Egln1 mRNA levels in indicated tissues from TAM-treated 
Egln1F/F; HSA-Cre-ERT2 and Egln1+/+; HSA-Cre-ERT2 mice. Abbreviations: soleus (Sol.), 
plantaris (Plant.), tibialis anterior (T.A.), gastrocnemius (Gastroc.), quadriceps (Quad.). Data 
shown are mean fold changes ± SEM. *p<0.05, Student’s t-test, differences in mRNA levels 
in Egln1F/F; HSA-Cre-ERT2 mice compared to Egln1+/+; HSA-Cre-ERT2 mice.
(B) Immunoblots of extracts from Sol. muscle of TAM-treated Egln1F/F; HSA-Cre-ERT2 
and Egln1+/+; HSA-Cre-ERT2 mice. Egln1 WT (+) and knockout (Δ) MEFs were included 
for comparison.
(C) MI size after cardiac I/R injury in TAM-treated Egln1F/F; HSA-Cre-ERT2 and Egln1+/+; 
HSA-Cre-ERT2 mice. Data shown are means ± SEM, n = 6 mice per group. *p<0.05, 
Student’s t-test. Representative photographs of TTC-stained hearts are shown.
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(D) PCR genotyping of the heart and quadriceps (Quad) of ‘donor’ and ‘recipient’ parabiosis 
mice. Donor mice were TAM-treated Egln1F/F; HSA-Cre-ERT2 and Egln1+/+; HSA-Cre-
ERT2 mice, as indicated. Egln1 primer set 1 amplifies WT and floxed (FL) alleles, and 
primer set 2 amplifies the deleted allele (Δ).
(E) Representative serum samples from parabiosis ‘donor’ and ‘recipient’ mice before and 2 
hours after i.v. injection of Evan’s blue (EB) dye.
(F) MI size after cardiac I/R injury in WT mice that were surgically conjoined to either a 
TAM-treated Egln1F/F; HSA-Cre-ERT2 mouse or a TAM-treated Egln1+/+; HSA-Cre-ERT2 
mouse. WT ‘recipient’ mice were subjected to cardiac I/R and MI size quantified 24 hours 
later. Data shown are means ± SEM, n = 6 Egln1F/F; HSA-Cre-ERT2 and n = 8 Egln1+/+; 
HSA-Cre-ERT2 mice. *p<0.05, Student’s t-test, difference in MI size in WT mice conjoined 
to Egln1F/F; HSA-Cre-ERT2 mice vs. WT mice conjoined to Egln1+/+; HSA-Cre-ERT2 mice. 
Representative photographs of TTC-stained hearts are shown.
See also Figure S2.
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Figure 4. The TRP Metabolite Kynurenic Acid is Necessary and Sufficient for Remote Cardiac 
I/R Protection
(A) Volcano plot depicting fold change and statistical significance in ion counts for serum 
metabolites in TAM-treated Egln1F/F; HSA-Cre-ERT2 mice compared to Egln1+/+; HSA-
Cre-ERT2 mice. Abbreviations: KYNA – kynurenic acid; αKG – alpha-ketoglutarate; TRP – 
tryptophan; NAM – niacinamide; NMN – n-methyl-nicotinamide. Metabolites above the 
dotted line are those that differ with p<0.05 (Student’s t-test, n=6). TRP metabolites are 
shown in red.
(B) Volcano plot depicting fold change and statistical significance of serum metabolites in 
mice given FG-4497 compared to Veh-treated animals. Labeled are the TRP metabolites 
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KYNA, Anthranilate, and 5-hydroxyindoleacetic acid (HIAA). Metabolites above the dotted 
line are those that differ with p<0.05 (Student’s t-test, n=3). #HIAA was undetectable in 
serum of mice given FG-4497. TRP metabolites are shown in red.
(C) Diagram of TRP metabolism, including the rate-limiting pyrolase IDO, present in 
peripheral tissues, TDO, present in the liver, the IDO/TDO inhibitor 1-methyltryptophan (1-
MT), and the regulated kynurenine (KYN) aminotransferases (KAT). The direct product of 
KYN transamination by KATs, 4-(2-aminophenyl)-2,3-dioxobutanoate (not shown), is non-
enzymatically dehydrated to produce KYNA.
(D) MI size after cardiac I/R injury in TAM-treated Egln1F/F; HSA-Cre-ERT2 and Egln1+/+; 
HSA-Cre-ERT2 mice given the IDO/TDO inhibitor 1-methyltryptophan (1-MT) or vehicle 
(Veh.) for 3 days before I/R. Data shown are means ± SEM, n = 5 Egln1F/F; HSA-Cre-ERT2 
vehicle, n = 5 Egln1F/F; HSA-Cre-ERT2 1-MT, n = 3 Egln1+/+; HSA-Cre-ERT2 vehicle, n = 
4 Egln1+/+; HSA-Cre-ERT2 1-MT. * p<0.05, Student’s t-test, for designated comparisons.
(E) MI size after cardiac I/R injury in WT mice pretreated with 100 ng KYNA or Veh. i.p. 2-
hr before and 2 hr after in vivo cardiac I/R. Data shown are means ± SEM, n = 16 vehicle, 
n=14 KYNA. *p<0.05, Student’s t-test.
(F) MI size after cardiac I/R injury in WT mice given 40 mg/kg KYNA mimetic L689,560 
or Veh. i.p. immediately before I/R injury. Data shown are means ± SEM, n = 3 per group. 
*p<0.05, Student’s t-test.
(G) LVEDP in Langendorff assays after global I/R injury, with or without 100 nM KYNA 
present in the perfusate. Data shown are mean pressures ± SEM, n = 10 KYNA group and n 
= 9 control group. **p<0.01, Student’s t-test.
See also Figure S3.
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Figure 5. Altered Systemic αKG Metabolism in Egln1F/F HSA-Cre-ERT2 Mice Leads to 
Cardioprotection Through KYNA
(A) Fractional labeling of U-13C-KYNA in tissues. WT mice were infused with U-13C-TRP 
until serum isotopic equilibrium was reached and then given 50 mg/kg FG-4497 i.v. Tissues 
were harvest 30 minutes later. Shown are mean enrichment ± SEM, n = 2.
(B) αKG levels in liver and quadriceps (Quad) of TAM-treated Egln1F/F; HSA-Cre-ERT2 
and Egln1+/+; HSA-Cre-ERT2 mice. Shown are mean fold change ± SEM, n = 23, **p<0.01, 
*p<0.05, Student’s t-test, comparison between EglNf/f; HSA-Cre-ERT2 and Egln1+/+; HSA-
Cre-ERT2 mice.
(C) Hepatic αKG levels in WT mice given 50 mg/kg FG-4497 i.v. or Veh. Shown are mean 
fold change ± SEM, n = 5. **p<0.01 Student’s t-test.
(D) KYNA levels in serum and liver of mice given 1 mg/kg αKG or Veh. i.p. Shown are 
mean total ion counts (TIC) quantified by LC-MS, ± SEM, n = 3. *p<0.05, **p<0.01 
Student’s t-test.
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(E) MI size in WT mice treated as in (D) 2 hours before cardiac I/R injury. Data shown are 
means ± SEM, n = 4 vehicle, n=6 αKG. *p<0.05, Student’s t-test. Representative 
photographs of TTC-stained hearts are shown.
(F) LVEDP in Langendorff assays after global I/R injury with or without αKG present in the 
perfusate at the indicated concentrations. One group of mice was pretreated with 1 mg/kg 
αKG i.p. 45 minutes before sacrifice. Data shown are mean pressures ± SEM. *p<0.05, 
Student’s t-test, for differences at 30 minutes compared to control.
See also Figure S4.
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Figure 6. Egln Activity Regulates αKG Levels in a HIF-independent Manner
(A) αKG levels in WT MEFs given FG-4497 or cultured under 1% O2 conditions for 24 
hours. Data are normalized to internal standard and cell number, succinate TIC (Suc), or 
glutamate TIC (Glu). ***p<0.001, Student’s t-test, differences compared to untreated MEFs 
grown in 21% O2. Shown are mean ± SEM, n = 3.
(B) Immunoblots of WT MEFs treated as in (A).
(C) αKG / Glutamate ratios of Hepa-1c1c7 ARNT−/− cells stably expressing exogenous 
ARNT or GFP and treated with FG-4497 or 1% O2 for 24 hours. *p<0.05, **p<0.01, 
Student’s t-test, differences compared to untreated MEFs grown in 21% O2. Shown are 
mean ± SEM, n =8.
(D) Firefly luciferase activity in Hepa-1c1c7 expressing exogenous ARNT or GFP, as in (C), 
and harboring a HIF-responsive firefly luciferase reporter. Cells were treated with FG-4497 
or 1% O2 for 24 hours as indicated. Shown are mean ± SEM, n =8. *p<0.05, ***p<0.001, 
Student’s t-test, differences relative to untreated cells grown in 21% O2.
(E) Immunoblots of cells used in (C) and (D).
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(F) Total ion counts of 13C4-succinate (Suc) in WT 143B cells at indicated time points after 
addition of U-13C-dimethyl-αKG. Shown are mean ± SEM, n = 4. *p<0.05 and **p<0.01, 
Student’s t-test, comparisons designated.
See also Figure S5.
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